glp-1 pendulum probiotic Glucose Control 1 can decrease with age and lifestyle Pendulum Akkermansia Probiotic with Prebiotic

Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr

Get tested before starting and retest at three to six months

Tirzepatide came off the FDA shortage list in December 2024 (enforcement discretion ended March 2025)

Pooled analyses from trials such as SUSTAIN-6 and LEADER reported reductions in albuminuria and slower declines in estimated glomerular filtration rates (eGFR), with pronounced benefits observed in those with lower baseline eGFR (41)